Application of flow cytometry in pediatric hematology-oncology

Pediatric Blood and Cancer

Volumn 57, Issue 1, 2011, Pages 18-29

  Varma, Neelam ^a   Naseem, Shano ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Flow cytometry; Oncology; Pediatric

Indexed keywords

BCR ABL PROTEIN; MULTIDRUG RESISTANCE PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; B CELL LYMPHOMA; BLOOD GROUP TYPING; CANCER STEM CELL; CELL CYCLE; CELL FUNCTION; CHILDHOOD CANCER; DNA CONTENT; DRUG UPTAKE; EWING SARCOMA; FLOW CYTOMETRY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HLA SYSTEM; HUMAN; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM; SOLID TUMOR; T CELL LYMPHOMA;

ACUTE DISEASE; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; INFANT; MALE; NEOPLASMS; PROGNOSIS;

EID: 79955713108     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22954     Document Type: Review

References (97)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin 2009;59:225-249.
2. U.S cancer statistics working group. United States cancer statistics: 1999-2005 Incidence and mortality Web-based report. Atlanta (GA): Department of Health and Human Services, centre for disease control and prevention, and National cancer institute; 2009.
3. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasm. Blood 2008;111:3941-3967.
4. Subira D, Castanon S, Roman A, et al. Flow cytometry and the study of central nervous system disease in patients with acute leukemia. Br J Haematol 2001;112:381-384.
5. Peterson LC, Goolsby C. Flow cytometric immunophenotyping of hematological malignancies involving the blood and bone marrow. Rev Curr Diag Path 1997;4:187-195.
6. Weir EG, Borowitz MJ. Flow cytometry in diagnosis of acute leukaemia. Semin Hematol 2001;38:124-138.
7. Arber DA, Brunning RD, Le Beau MM, et al. Acute myeloid leukemia with recurrent abnormalities. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organisation classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp. 110-123.
8. Borowitz MJ, Chan JKC. B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organisation classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp. 171-175.
9. Weyl M, Arush M, Linn S, et al. Prognostic significance of DNA ploidy in childhood astrocytomas. Pediatr Hematol Oncol 1999;16:387-396.
10. Habermehl P, Knuf M, Schwarz M, et al. Flow-cytometric DNA analysis of intracranial tumors in children. Pathol Res Pract 2004;200:197-202.
11. Zamecnik J, Snuder M, Eckschlager T, et al. Pediatric intracranial ependymomas: Prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod Pathol 2003;16:980-991.
12. Katzenstein HM, Kent PM, London WB, et al. Treatment and outcome of 83 children with intraspinal neuroblastoma: The Pediatric Oncology Group Experience. J Clin Oncol 2001;19:1047-1055.
13. Freedman AS. Cell surface antigen in leukaemias and lymphomas. Cancer Invest 1996;14:252-276.
14. Paraskevas F. Clinical flow cytometry. In: Greer JP, Foerster J, Rodgers GM, et al., editors. Wintrobe's clinical hematology. Philadelphia: Lippincott Williams & Wilkins; 2009. pp. 21-49.
15. Borowitz MJ, Guenther KL, Shults KE, et al. Immunophenotyping of acute leukemia by flow cytometric analysis: Use of CD45 and right angle scatter to gate on leukemic blasts on three-colour analysis. Am J Clin Pathol 1993;100:534-540.
16. Look AT, Roberson P, Williams D. Prognostic significance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 1985;65:1079-1086.
17. Pui CH. Acute lymphoblastic leukemia. In: Litchtman MA, Kipps TJ, Kaushansky K, et al., editors. Williams hematology. New York McGraw Hill; 2006; pp. 1321-1342.
18. Borowitz MJ, Chan JKC. B lymphoblastic leukaemia/lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organisation classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp. 168-170.
19. Weerkamp F, Dekking E, Ng YY, et al. Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia 2009;23:1106-1117.
20. Raponi S, De Propris MS, Wai H, et al. An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia. Haematologica 2009;94:1767-1770.
21. Sevilla DW, Colovai AI, Emmons FN, et al. Hematogones: A review and update. Leuk Lymphoma 2010;51:10-19.
22. Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods 2000;243:59-75.
23. Pui CH, Behm FG, Singh B, et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990;75:174-179.
24. Pui CH, Hancock ML, Head DR, et al. Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. Blood 1993;82:889-894.
25. Matutes E, Morilla R, Catovsky D. Immunophenotyping. In: Lewis SM, Bain BJ, Bates I, editors. Dacie and Lewis practical haematology. Philadelphia: Churchill Livingstone; 2006. pp. 335-356.
26. Horibe K, Tsukimoto I, Ohno R. Clinicopathologic characterization of leukemia in Japanese children and young adults. Leukemia 2001;15:1256-1261.
27. Webb DK, Harrison G, Stevens RF, et al. Relationship between age at diagnosis, clinical features and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001;98:1714-1720.
28. Robinson LL. Down syndrome and leukemia. Leukemia 1992;6:5-7.
29. Kwong YL, Cheng G, Tang TS, et al. Transient myeloproliferative disorder in a Down's neonate with rearranged T-cell receptor β gene and evidence of in vivo maturation demonstrated by dual-colour flow cytometric DNA ploidy analysis. Leukemia 1993;7:1667-1671.
30. Bain BJ, Barnett D, Linch D, et al. General haematology task force of the British committee for standards in haematology (BCSH). British Society of Haematology. Revised guideline on immunophenotyping in acute leukaemia and chronic lymphoproliferative disorders. Clin Lab Hematol 2002;24:1-13.
31. Brunning RD, Matutes E, Borowitz M, et al. Acute leukemias of ambiguous lineage. In: Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organisation classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp. 106-107.
32. Borowitz MJ, Bene MC, Harris NL, et al. Acute leukemias of ambigious lineage. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organisation classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp. 150-155.
33. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the immunological characterization of leukemias (EGIL). Leukemia 1995;9:1783-1786.
34. Powari M, Varma N, Varma S, et al. Flow cytometric characterization of phenotype, DNA indices and p53 gene expression in 55 cases of acute leukemia. Anal Quantum Cytol Histol 2002;24:159-165.
35. Lanzkowsky P. Manual of pediatric hematology and oncology. California: Elseiver Academic Press; 2005. pp. 453-511.
36. Stetler-Stevenson M, Braylan RC. Flow cytometric analysis of lymphomas and lymphoproliferative disorders. Semin Hematol 2001;38:111-123.
37. Jennings CD, Foon KA. Recent advances in flow cytometry: Application to the diagnosis of hematologic malignancy. Blood 1997;70:2863-2892.
38. Borowitz MJ, Croker BP, Metzgar RS. Immunohistochemical analysis of the distribution of lymphocyte subpopulations in Hodgkin's disease. Cancer Treat Rep 1982;66:667-674.
39. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102:394-403.
40. Scott BL, Wells DA, Loken MR, et al. Validation of a flow cytometric scoring system as a prognostic indicator for post transplantation outcome in patients with myelodysplastic syndrome. Blood 2008;112:2681-2686.
41. Veltroni M, Sainati L, Zecca M, et al. Advanced pediatric myelodysplastic syndromes: Can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool? Pediatr Blood Cancer 2009;52:357-363.
42. van Dongen JJM, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 1998;352:1731-1738.
43. Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003;123:243-252.
44. Attarbaschi A, Mann G, Panzer-Grumayer R, et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: The Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol 2008;20:3046-3050.
45. Elorza I, Palacio C, Dapena JL, et al. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica 2010;95:936-941.
46. Lankester AC, Bierings MB, van Wering ER, et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia 2010;24:1462-1469.
47. Irving J, Jesson J, Virgo P, et al. On behalf of the UKALL Flow MRD group and UK MRD steering group. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica 2009;94:870-874.
48. van der Velden VJH, Willemse MJ, van der Schoot CE, et al. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 2002;16:928-936.
49. van der Velden VJH, Wijkhuijs JM, Jacobs DCH, et al. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 2002;16:1372-1380.
50. van der Velden VH, van Dongen JJ. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol 2009;538:115-150.
51. Campana D. Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep 2010;5:169-176.
52. Campana D, Coustan-Smith E, Behm FG. The definition of remission in acute leukemia with immunological techniques. Bone marrow transplant 1991;8:429-437.
53. Al-Mawali A, Gillis D, Hissaria P, et al. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol 2008;129:934-945.
54. Hooijkaas H, Hahlen K, Adriaasen HJ, et al. Terminal deoxynucleotidly transferase (TdT) positive cells in the cerebrospinal fluid and development of overt CNS leukemia: A 5-year follow-up study in 113 children with TdT- positive leukemia and non-Hodgkin's lymphoma. Blood 1989;74:416-422.
55. Wang YZ, Chang Y, Zhu HH, et al. Application of CD123 in detection of minimal residual disease in acute promyelocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006;14:427-432.
56. Veltroni M, De Zen L, Sanzari MC, et al. On behalf of the I-BFM-ALL-FCM-MRD-Study group. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: Implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica 2003;88:1245-1252.
57. Stass S, Mirro J, Melvin S, et al. Lineage switch in acute leukemia. Blood 1984;64:701-708.
58. Bjorklund E, Gruber A, Mazur J, et al. CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: Application for MRD detection in leukemia patients. Int J Hematol 2009;90:292-302.
59. Petrausch U, Haley D, Miller W, et al. Polychromatic flow cytometry: A rapid method for the reduction and analysis of complex multiparameter data. Cytometry A 2006;69:1162-1173.
60. Coustan-Smith E, Ribeiro RC, Stow P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006;108:97-102.
61. Siena S, Bregni M, Di Nicola M, et al. Milan protocol for clinical CD34+ cell estimation in peripheral blood for autografting in patients with cancer. In: Wunder E, Solvalat H, Henon PR, et al., editors. Hematopoietic stem cells: The Milhouse manual. Dayton: Alphamed; 1994. pp. 23-30.
62. Bender JG, Unverzagt K, Walker D. Guidelines for determination of CD34+ cells by flow cytometry: Application to the harvesting and transplantation of peripheral blood stem cells. In: Wunder E, Solvalat H, Henon PR, et al., editors. Hematopoietic stem cells: The Milhouse manual. Dayton: Alphamed; 1994. pp. 31-43.
63. Gramata JW, Keeney M, Sutherland DR. Enumeration of CD34+hematopoietic stem and progenitor cells. Current protocols in cytometry, unit 6.4. New York: Wiley-Liss; 1999. pp. 1-22.
64. Owens MA, Loken MR. Peripheral blood stem cell quantification. In flow cytometric principals for clinical laboratory practice. New York: Wiley-Liss; 1995. pp. 112-128.
65. Sutherland DR, Armand K, Rakesh N. Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Hematol 1994;22:1003-1010.
66. Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996;5:213-236.
67. Gramata JW, Kraan J, Keeney M, et al. Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy 2003;5:55-65.
68. Gratama JW, Orfao A, Barnett D. Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells. Cytometry 1998;34:128-142.
69. Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organisation classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
70. Basso G, Putti MC, Cantu-Rajnoldi A, et al. The immunophenotype in infant ALL: Correlation with clinical outcome. An Italian multicenter study. Br J Haematol 1992;81:184-191.
71. Sievers EL, Lange BJ, Alonzo TA, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: Results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003;101:3398-3406.
72. Borowitz MJ, Hunger SP, Carroll SJ, et al. Predictability of the t (1; 19) (q23; p13) from surface antigen phenotype: Implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: A Pediatric Oncology Group study. Blood 1993;82:1086-1090.
73. Worth LL, Jeha SS, Kleinerman ES. Biologic response modifiers in Pediatric cancer. In: Copps MJ, Tubergen DG, Arceci RJ, editors. Hematology/oncology clinics of North America. Pediatric oncology in 21st century, Part 1. Philadelphia: WB Saunders Company; 2001. pp. 723-740.
74. Perez OD, Nolan GP. Phospho-proteomic immune analysis by flow cytometry: From mechanisms to translational medicine at the single-cell level. Immunol Rev 2006;210:208-228.
75. Chang RL, Yeh CH, Albitar M. Quantification of intracellular proteins and monitoring therapy using flow cytometry. Curr Drug Targets 2010;11:994-999.
76. Maino VC, Picker LJ. Identification of functional subsets by flow cytometry: Intracellular detection of cytokine expression. Cytometry 1998;34:207-215.
77. Pala P, Hussell T, Openshaw PJM. Flow cytometric measurement of intracellular cytokines. J Immunol Methods 2000;243:107-124.
78. Blessing JJH, Fleisher TA. Cell function-based flow cytometry. Semin Hematol 2001;38:169-178.
79. Lehman AK, Sohnes S, Halstensen A. Phagocytosis: Measurement by flow cytometry. J Immunol Methods 2000;243:249-255.
80. Darzynkiewicz K, Bedner E, Smolewski P. Flow cytometry in analysis of cell cycle and apoptosis. Semin Hemtol 2001;38:179-193.
81. Bray RA, Gebel HM. Transplantation immunophenotyping. In: Stewart CC, Nicholson JKA, editors. Immunophenotyping. New York: Wiley-Liss; 2000. pp. 321-332.
82. Krishan A, Arya P. Monitoring of cellular resistance to cancer chemotherapy. Hematol Oncol Clin North Am 2002;16:357-372.
83. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self renewal. Clin Cancer Res 2010;16:3113-3120.
84. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett 2008;268:1-9.
85. Hadnagy A, Gaboury L, Beaulieu R, et al. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 2006;312:3701-3710.
86. Davis BH, Holden JT, Bene MC, et al. Bethesda international consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical Indications. Cytometry part B (clinical cytometry) 2006;72B:S5-S13.
87. Wood BL, Arroz M, Barnett D, et al. Bethesda international consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry part B (clinical cytometry) 2006;72B:S14-S22.
88. Greig B, Oldaker T, Warzynski M, et al. Bethesda international consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Recommendations for training and education to perform clinical flow cytometry. Cytometry part B (clinical cytometry) 2006;72B:S23-S33.
89. Alvarez DF, Helm K, DeGregori J, et al. Publishing flow cytometry data. Am J Physiol Lung Mol Physiol 2010;298:L127-L130.
90. Rabson AR. Flow cytometry in diagnosis of brain tumors. Neurosurg Clin N Am 1994;5:135-146.
91. Lopes JM, Hannisdal E, Bierkehagen B, et al. Synovial sarcoma. Evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers. Anal Cell Pathol 1998;16:45-62.
92. Koksal Y, Reisli I, Dogu F, et al. Can flow-cytometry be used at diagnosis and follow-up in neuroblastoma with bone marrow involvement? Turk J Cancer 2006;36:27-30.
93. Nagai J, Ishida Y, Koga N, et al. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry. J Pediatr Hematol Oncol 2000;22:20-26.
94. Komada Y, Zhang XL, Zhou YW, et al. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma. Cancer 1998;82:591-599.
95. Dubois SG, Epling L, Teague J, et al. Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatr Blood Cancer 2010;54:13-18.
96. Komuro H, Saihara R, Shinya M, et al. Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. J Pediatr Surg 2007;41:2040-2045.
97. Nelson R. Metastatic disease in pediatric cancer shows strikingly high levels of progenitor cells. Clin Cancer Res 2009;15:4561-4571.